Growth in the US enzymes market will total 3.0% percent per year through 2019, reaching $2.2 billion. Advances will be driven by changes in healthcare and the growth of “personalized” medicine. Demand for biofuel enzymes will expand less than one percent, as public support for ethanol containing fuels declines.
This report segments the enzymes market by Market and Product. Data is provided in million US dollars.
Enzyme markets include:
Food and beverage processing
Research and biotechnology
The specialty enzyme markets -- research and biotechnology and diagnostic testing -- will post the fastest gains, as the growing use of “personalized medicine” will drive testing rates and the development of advanced pharmaceuticals. Biofuels are forecast to remain the largest market through 2019, although demand is forecast to slow appreciably.
Enzyme products include:
Carbohydrases are forecast to remain the largest segment in the US enzyme market, supported by the dominant role of the biofuels industry. However, polymerases and nucleases are expected to post the fastest gains through 2010, driven by the development and uptake of molecular diagnostic testing.
The US enzymes industry ranges from small, privately held supplier to large, multinational manufacturers, as well as healthcare and biotechnology firms. The industry has seen a number of notable acquisitions and divestitures in recent year. Leading enzyme suppliers to the US market include AB Enzymes, Agilent, BASF, Chr Hansen, DuPont, GlaxoSmithKline, Illumina, New England Biolabs, Novozymes, Roche, and Royal DSM.